$313 Million is the total value of Medicxi Ventures Management (Jersey) Ltd's 6 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CNTA | CENTESSA PHARMACEUTICALS PLCsponsored ads | $129,161,626 | +4.5% | 19,963,157 | 0.0% | 41.24% | +19.1% | |
| PCVX | Sell | VAXCYTE INC | $53,523,545 | -18.5% | 1,049,893 | -20.2% | 17.09% | -7.2% |
| PHAT | PHATHOM PHARMACEUTICALS INC | $39,000,212 | -27.6% | 3,760,869 | 0.0% | 12.45% | -17.5% | |
| MRUS | MERUS N V | $37,728,000 | -10.4% | 1,600,000 | 0.0% | 12.04% | +2.0% | |
| AURA BIOSCIENCES INC | $27,267,831 | -27.4% | 3,039,892 | 0.0% | 8.71% | -17.2% | ||
| NEWAMSTERDAM PHARMA COMPANYordinary shares | $26,543,476 | -22.2% | 2,869,565 | 0.0% | 8.47% | -11.4% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Francesco De Rubertis #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-10-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PHATHOM PHARMACEUTICALS INC | 16 | Q3 2023 | 69.8% |
| MERUS N V | 16 | Q3 2023 | 25.3% |
| VAXCYTE INC | 14 | Q3 2023 | 44.5% |
| OBSEVA SA | 12 | Q3 2022 | 5.7% |
| CENTESSA PHARMACEUTICALS PLC | 10 | Q3 2023 | 71.3% |
| AURA BIOSCIENCES INC | 8 | Q3 2023 | 22.9% |
| CHECKMATE PHARMACEUTICALS IN | 8 | Q2 2022 | 12.7% |
| NEWAMSTERDAM PHARMA COMPANY | 4 | Q3 2023 | 11.4% |
| SYNTHORX INC | 1 | Q4 2019 | 43.1% |
View Medicxi Ventures Management (Jersey) Ltd's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-15 |
| 13F-HR | 2024-02-01 |
| 3 | 2024-01-26 |
| 13F-HR | 2023-10-18 |
| 13F-HR | 2023-07-19 |
| 13F-HR | 2023-04-27 |
| 13F-HR | 2023-01-31 |
| 13F-HR | 2022-10-25 |
| 13F-HR/A | 2022-08-03 |
| 13F-HR | 2022-08-03 |
View Medicxi Ventures Management (Jersey) Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.